Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Pradeep Ventrapati"'
Autor:
Anant Ramaswamy, Vasu Babu, Rushabh Kothari, Ram Abhinav, Ashwin Desouza, Pradeep Ventrapati, Amit Kumar, Akhil Kapoor, Shasanka Das, Reena Engineer, Avanish Saklani, Vikas Ostwal
Publikováno v:
South Asian Journal of Cancer, Vol 11, Iss 04, Pp 293-298 (2022)
Abstract Anant Ramaswamy Introduction The overall survival (OS) of metastatic colorectal cancers (mCRCs) in clinical practice and resource-constrained low- and middle-income countries (LMICS) like India is not known. Materials and Methods Data of
Externí odkaz:
https://doaj.org/article/533f5e1e911b4763a92a83f2cb8ca9ee
Autor:
Jyoti Bajpai, Pradeep Ventrapati, Shalaka Joshi, Tabassum Wadasadawala, Sushmita Rath, Rima Pathak, Ravindra Nandhana, Samarpita Mohanty, Qurratulain Chougle, Mitchelle Engineer, Nissie Abraham, Jaya Ghosh, Nita Nair, Seema Gulia, Palak Popat, Patil A, Tanuja Sheth, Sangeeta Desai, Meenakshi Thakur, Venkatesh Rangrajan, Vani Parmar, R. Sarin, S. Gupta, R.A. Badwe
Publikováno v:
Breast, Vol 60, Iss , Pp 177-184 (2021)
Background: Young (≤40 years) breast cancers (YBC) are uncommon, inadequately represented in trials and have unique concerns and merit studying. Methods: The YBC treated with a curative intent between 2015 and 2016 at our institute were analysed. R
Externí odkaz:
https://doaj.org/article/24d59e341e7a409290b005a5644e0797
Autor:
Suresh Kumar Bondili, Bhausaheb Bagal, Abhinav Zawar, Pradeep Ventrapati, Jayashree Thorat, Anant Gokarn, Sachin Punatar, Lingaraj Nayak, Avinash Bonda, Hashmukh Jain, Manju Sengar, Navin Khattry
Publikováno v:
JCO Global Oncology, Vol , Iss 7, Pp 361-367 (2021)
PURPOSEThe prognosis of relapsed and refractory multiple myeloma (RRMM) that is refractory to bortezomib and lenalidomide is very poor wherein the median survival is between 3 and 9 months. We did this retrospective analysis to study the pattern of u
Externí odkaz:
https://doaj.org/article/fb2754aebd0d47ab94f65b5b6f8c96df
Autor:
Vanita Noronha, George Abraham, Vijay Patil, Amit Joshi, Nandini Menon, Abhishek Mahajan, Amit Janu, Srushti Jain, Vikas T Talreja, Akhil Kapoor, Gunjesh Kumar Singh, Satvik Khaddar, Kushal Gupta, Narmadha Rathinasamy, Sujay Srinivas, Amit Agrawal, Pradeep Ventrapati, Kumar Prabhash
Publikováno v:
Cancer Medicine, Vol 10, Iss 5, Pp 1525-1534 (2021)
Abstract Background Checkpoint inhibitors (Nivolumab and Pembrolizumab) are approved for multiple indications in solid tumors. However access to these therapies is limited in low and middle income countries. Hence we performed an audit to identify ac
Externí odkaz:
https://doaj.org/article/5b5c8311ba364527bdcb8ecc4d6fbd9b
Autor:
Anant Ramaswamy, Rushabh Kothari, Ashwin Desouza, Tarachand Gupta, Sandeep Bairwa, Akhil Kapoor, Amit Kumar, Pradeep Ventrapati, Mukta Ramadwar, Sarika Mandavkar, Nita Chavan, Avanish Saklani, Vikas Ostwal
Publikováno v:
South Asian Journal of Cancer, Vol 8, Iss 3, Pp 160-165 (2019)
Background: Data regarding the practice of adjuvant chemotherapy, specifically with modified CAPOX, and survival outcomes in operated colon cancer patients from a nontrial cohort in a lower-middle income and low prevalence nation like India is scarce
Externí odkaz:
https://doaj.org/article/b9eb59c6697646619046f6edc2560c74
Publikováno v:
Indian Journal of Medical and Paediatric Oncology. 44:365-370
Radiation recall dermatitis (RRD) is an extremely rare phenomenon. A variety of factors such as antineoplastic agents, pharmaceutical agents, physical and environmental factors have been proposed to be the underlying cause of RRD. Only a handful case
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e637b1cd52a1529b93096053d7e1b2ca
https://doi.org/10.1055/s-0043-1761263
https://doi.org/10.1055/s-0043-1761263
Autor:
Abhinav Zawar, Suresh Kumar Bondili, Manju Sengar, Lingaraj Nayak, Navin Khattry, Jayashree Thorat, Pradeep Ventrapati, Hashmukh Jain, Anant Gokarn, Sachin Punatar, Bhausaheb Bagal, Avinash Bonda
Publikováno v:
JCO Global Oncology
PURPOSE The prognosis of relapsed and refractory multiple myeloma (RRMM) that is refractory to bortezomib and lenalidomide is very poor wherein the median survival is between 3 and 9 months. We did this retrospective analysis to study the pattern of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcc9fe8f1829aa1409051ca61bafb552
https://doi.org/10.1200/go.20.00228
https://doi.org/10.1200/go.20.00228
Autor:
Satvik Khaddar, Nandini Menon, Amit Agrawal, Kumar Prabhash, Vanita Noronha, Abhishek Mahajan, Vijay Patil, K. Gupta, George Abraham, Sujay Srinivas, Akhil Kapoor, Vikas Talreja, Narmadha Rathinasamy, Amit Janu, Gunjesh Kumar Singh, Pradeep Ventrapati, Srushti Jain, Amit Joshi
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 5, Pp 1525-1534 (2021)
Cancer Medicine, Vol 10, Iss 5, Pp 1525-1534 (2021)
Background Checkpoint inhibitors (Nivolumab and Pembrolizumab) are approved for multiple indications in solid tumors. However access to these therapies is limited in low and middle income countries. Hence we performed an audit to identify accessibili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d3d1489ee5e8c43784ff108b3c10585
https://pubmed.ncbi.nlm.nih.gov/33591635
https://pubmed.ncbi.nlm.nih.gov/33591635
Publikováno v:
Journal of Cancer Research and Therapeutics, Vol 13, Iss 1, Pp 145-147 (2017)
Hemangiopericytomas (HPCs) are rare soft tissue tumors. The eyelid is a very uncommon site for these tumors, and an anaplastic variant of HPC in the eyelid has not been reported before. A 44-year-old male presented with complaints of slowly progressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d982a9aac35c7d6b71e91c0a6120fe0c
http://www.cancerjournal.net/article.asp?issn=0973-1482
http://www.cancerjournal.net/article.asp?issn=0973-1482
Autor:
Tara Chand Gupta, Ashwin Desouza, Anant Ramaswamy, Akhil Kapoor, Pradeep Ventrapati, Prachi Patil, Avanish Saklani, Vikas Ostwal, Rushabh Kothari, Supreeta Arya, Suman Kumar, Sandeep Kumar Bairwa, Mukta Ramadvar, Amit Kumar
Publikováno v:
Journal of Clinical Oncology. 36:857-857
857 Background: Data regarding survival and outcomes in operated colon cancer patients from a lower-middle income and low prevalence nation like India is scarce. Methods: Patients who underwent curative resection for non-metastatic, non-rectal colon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::826971be7892081a52b5059f84559ab5
https://doi.org/10.1200/jco.2018.36.4_suppl.857
https://doi.org/10.1200/jco.2018.36.4_suppl.857